Thera-SAbDab

EVOLOCUMAB

>   Structural Summary
TherapeuticEvolocumab
TargetPCSK9
Heavy ChainEVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
Light ChainESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyAbgenix XenoMouse
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedAmgen, Amgen Astellas BioPharma, University Hospital Inselspital
Conditions ApprovedCoronary disorders, Hypercholesterolaemia, Hyperlipoproteinaemia type IIa, Myocardial infarction, Stroke
Conditions ActiveHyperlipidaemia
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]